A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

NCT00324129 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: MGCD0103

Sponsor

Mirati Therapeutics Inc.